Short Interest in Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Declines By 94.5%

Posted by Lauren Steadman on Jul 25th, 2026

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR – Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 3,571 shares, a decline of 94.5% from the June 30th total of 65,392 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 99,268 shares, the days-to-cover ratio is currently 0.0 days.

Cuprina Holdings (Cayman) Stock Up 0.9%

Shares of NASDAQ CUPR traded up $0.03 during midday trading on Friday, reaching $3.34. 12,799 shares of the company traded hands, compared to its average volume of 1,379,201. The business’s 50-day moving average price is $3.91. Cuprina Holdings has a 12 month low of $1.76 and a 12 month high of $76.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.35 and a current ratio of 2.35.

Cuprina Holdings (Cayman) (NASDAQ:CUPR – Get Free Report) last posted its earnings results on Monday, April 27th. The company reported ($0.40) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Cuprina Holdings (Cayman) from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cuprina Holdings (Cayman) currently has a consensus rating of “Sell”.

Get Our Latest Research Report on CUPR

Cuprina Holdings (Cayman) Company Profile

(Get Free Report)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.